

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7365463

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
INNATE PHARMA	03/22/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	OREGA BIOTECH
<b>Street Address:</b>	ESPACE EUROPÉEN, BÂTIMENT G, 15 CHEMIN DU SAQUIN
<b>City:</b>	ECULLY
<b>State/Country:</b>	FRANCE
<b>Postal Code:</b>	69130
<b>Name:</b>	INNATE PHARMA
<b>Street Address:</b>	117 AVENUE DE LUMINY - BP 30191
<b>Internal Address:</b>	CEDEX 09
<b>City:</b>	MARSEILLE
<b>State/Country:</b>	FRANCE
<b>Postal Code:</b>	13276
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16477506
Application Number:	16370789
Application Number:	16443744
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(858)707-4001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	8587074000
<b>Email:</b>	efiling@knobbe.com
<b>Correspondent Name:</b>	KNOBBE, MARTENS, OLSON & BEAR, LLP
<b>Address Line 1:</b>	2040 MAIN STREET, 14TH FLOOR
<b>Address Line 4:</b>	IRVINE, CALIFORNIA 92614
<b>ATTORNEY DOCKET NUMBER:</b>	INNAT.041P1/.043A/.045NP
<b>NAME OF SUBMITTER:</b>	BRENDEN GINGRICH

<b>SIGNATURE:</b>	/Brenden Gingrich/
<b>DATE SIGNED:</b>	06/03/2022
<b>Total Attachments: 8</b> source=INNAT - Patent Assignment - Innate to Orega - INNAT.041P1_043A_045NP#page1.tif source=INNAT - Patent Assignment - Innate to Orega - INNAT.041P1_043A_045NP#page2.tif source=INNAT - Patent Assignment - Innate to Orega - INNAT.041P1_043A_045NP#page3.tif source=INNAT - Patent Assignment - Innate to Orega - INNAT.041P1_043A_045NP#page4.tif source=INNAT - Patent Assignment - Innate to Orega - INNAT.041P1_043A_045NP#page5.tif source=INNAT - Patent Assignment - Innate to Orega - INNAT.041P1_043A_045NP#page6.tif source=INNAT - Patent Assignment - Innate to Orega - INNAT.041P1_043A_045NP#page7.tif source=INNAT - Patent Assignment - Innate to Orega - INNAT.041P1_043A_045NP#page8.tif	

**CONTRAT DE CESSIION DE QUOTE-PART DE  
BREVETS**

**DEED OF ASSIGNMENT OF PATENTS CO-  
OWNERSHIP SHARE**

**ENTRE LES SOUSSIGNEES :**

**INNATE PHARMA SA**, 117 Avenue de Luminy, 13009  
Marseille, France

représentée aux effets des présentes  
par son représentant dûment habilité,

ci-après appelée le "**Cédant**" ou « **INNATE  
PHARMA** »,

D'UNE PART,

**ET**

**OREGA BIOTECH SAS**, 15 chemin du Saquin,  
L'espace Européen, Bâtiment G, 69130 Ecully, France

représentée aux effets des présentes par  
son représentant dûment habilité,

ci-après appelée le "**Cessionnaire**" ou « **OREGA  
BIOTECH** »,

D'AUTRE PART,

**IL EST EXPOSE ET CONVENU CE QUI SUIT :**

Le Cédant a déposé et est seul propriétaire des brevets  
et demandes de brevet en Annexe 1.

**IL A ETE DIT ET CONVENU CE QUI SUIT:**

1. Par la présente, le Cédant cède au Cessionnaire, qui  
accepte, une partie de sa quote-part des droits de  
propriété qu'il détient sur tout brevet ou demande de  
brevet protégeant les inventions décrites et protégées  
par les demandes internationales de brevets WO  
2018/167267, WO 2019/096900 et WO 2019/243252,  
notamment :

- chacune des trois demandes internationales de  
brevets WO 2018/167267, WO 2019/096900 et  
WO 2019/243252 ;
- tout brevet ou demande de brevet en  
découlant, en ce compris toute demande  
divisionnaire ;

**BETWEEN THE UNDERSIGNED:**

**INNATE PHARMA SA**, 117 Avenue de Luminy,  
13009 Marseille, France

represented for the purpose of this assignment  
by its Representative duly empowered,

hereinafter referred to as the "**Assignor**" or  
"**INNATE PHARMA**",

ON ONE HAND,

**AND**

**OREGA BIOTECH SAS**, 15 chemin du Saquin,  
L'espace Européen, Bâtiment G, 69130 Ecully, France

represented for the purpose of this assignment  
by its Representative duly empowered,

hereinafter referred to as the "**Assignee**" or «  
**OREGA BIOTECH** »,

ON THE OTHER HAND,

**THE FOLLOWING HAS BEEN STATED AND  
AGREED UPON :**

The Assignor has filed and is the sole owner of the  
patents and patent applications listed in Annexe 1.

**NOW THEREFORE IT HAS BEEN AGREED AS  
FOLLOWS:**

1. The Assignor hereby assigns to the Assignee, who  
accepts, a part of its share of the rights of ownership  
on any patent or patent application protecting the  
inventions described and protected by international  
patent applications WO 2018/167267, WO  
2019/096900 and WO 2019/243252, including :

- each of the three international patent  
applications WO 2018/167267,  
WO 2019/096900 and WO 2019/243252;
- any resulting patent or patent application,  
including any divisional application;

- tout brevet ou demande de brevet ayant la ou les mêmes priorités que les demandes internationales précitées, notamment la demande de brevet US 2019/0218304 ;

(ci-après les « Brevets » dont une liste à date, fournie par INNATE PHARMA, figure en Annexe 1).

Il est entendu que la présente cession de quote-part de propriété exclut tout perfectionnement des Brevets.

2. En conséquence, les Parties deviennent copropriétaires des Brevets et du droit de priorité associé de la manière suivante :

- INNATE PHARMA détiendra 50% de la copropriété des Brevets ;
- OREGA BIOTECH détiendra 50% de la copropriété des Brevets.

Les Parties conviennent que la copropriété des Brevets et du droit de priorité associé est régie par les dispositions du Contrat de Licence et pour les points non réglés, par le règlement de copropriété signé par les Parties à la date des présentes.

3. La présente cession de quote-part de propriété entre INNATE PHARMA et OREGA BIOTECH étant consentie par application de la sentence arbitrale rendue par le WIPO (réf. : WIPOA251119) en date du 9 décembre 2021 et à titre de régularisation de la propriété des Brevets, celle-ci intervient sans contrepartie pécuniaire.

4. INNATE PHARMA déclare avoir la capacité et tous les droits nécessaires pour consentir la cession de quote-part de propriété des Brevets.

5. INNATE PHARMA s'engage à procéder à l'inscription de la présente cession sur tout registre des brevets tenu par un Office des brevets concerné par la présente cession, et à supporter l'ensemble des frais et taxes afférents auxdites inscriptions et formalités.

Tous pouvoirs sont donnés au porteur d'une copie de la présente pour procéder à l'inscription de cette cession de quote-part de Brevets et du droit de priorité associés auprès des Offices de brevet concernés.

6. Conformément à l'article 731 du Code général des impôts, la présente cession donnera lieu au paiement d'un droit d'enregistrement fixe de 125 €. INNATE PHARMA supportera ce coût et s'engage à accomplir les formalités d'enregistrement auprès de l'administration fiscale dans un délai de 30 jours.

- any patent or patent application having the same priority or priorities as the above international applications, including US patent application 2019/0218304;

(hereafter the "Patents", a list of which to date, provided by INNATE PHARMA, is found in Annexe 1).

It is understood that this assignment of share of ownership excludes any improvements of Patents.

2. Therefore, the Parties become co-owners of the Patents and of the priority right attached to them as follows:

- INNATE PHARMA will hold 50% of the co-ownership of the Patents;
- OREGA BIOTECH will hold 50% of the co-ownership of the Patents.

The Parties agree that the the co-ownership of the Patents and of the priority right attached to them is governed by the Licence Agreement and, for all aspects not covered, by the regulation executed by the Parties this day.

3. The assignment of share of ownership between INNATE PHARMA and OREGA BIOTECH being granted by virtue of an arbitration award rendered by WIPO (ref: WIPOA251119) on December 9th 2021 and as part of the regularization of the ownership of the Patents, it is therefore assigned by INNATE PHARMA without any monetary consideration.

4. INNATE PHARMA represents that it has all rights and capacity to grant the assignment of share of ownership of the Patents.

5. INNATE PHARMA undertakes to record this assignment at any patent register maintained by a Patent Office affected by this assignment, and to bear all costs, expenses and taxes pertaining to such recordal and formalities.

Full powers are granted to holders of a copy thereof to proceed with the recordal of the assignment of share of ownership of the Patents and of the priority right attached to them with the concerned Patent Offices.

6. Pursuant to Section 731 of the French tax code, the present assignment shall be subject to a fixed registration tax of €125. INNATE PHARMA shall bear such cost and undertakes to carry-out the requisite registration formalities with the French tax authorities within 30 days.

7. La présente cession de quote-part des Brevets entrera rétroactivement en vigueur, respectivement s'agissant de chacun des Brevets, à la date de dépôt de chacun des Brevets transférés ou, le cas échéant, à leur date de priorité.

8. En cas de divergences entre la version française et la version anglaise du présent contrat, la version française prévaudra.

7. The present assignment of a co-ownership share of the Patents shall enter into force retroactively, with respect to each of the Patents, on the filing date of each of the Patent assigned or, if applicable, on its priority date.

8. In case of discrepancies between the French version and the English version of this agreement, the French version shall prevail.

[SIGNATURES SUR LA PLAGE SUIVANTE]

[SIGNATURE PAGE FOLLOWS]

03

In 2 original copies (en 2 exemplaires originaux)

Made in (fait à) Marseille

On (le) 22 day of (jour de) March 2022

INNATE PHARMA SA  
Assignor (Cédant)

Full first name and surname and business capacity of the signatory  
*MOREL, Yannis, Executive Vice President*

Signature et cachet de l'entité :



Made in (fait à) Ecully

On (le) 30 day of (jour de) March 2022

OREGA BIOTECH SAS  
Assignee (Cessionnaire)

Full first name and surname and business capacity of the signatory  
*BASTID, Jeremy, Chief Executive Officer*

Signature et cachet de l'entité:

OREGA BIOTECH  
L'Espace Européen, Bât G,  
15 chemin du Saquin, 69130 Ecully  
Tél. : +33 (0)4 37 49 87 20  
RCS Lyon 520 831 818

**ANNEXE I**

Order Number	Country	Country Name	Sub Case	Application Number	Filing Date	Publication Number	Patent Number	Status	Title
CD39-6	AU	Australia		2018235092	16-Mar-2018			Pending	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-6	BR	Brazil		BR 11 2019 018685-9	16-Mar-2018			Pending	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-6	CA	Canada		3051640	16-Mar-2018	3051640		Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-6	CN	China (People's Republic)		2018800161033	16-Mar-2018	C.N. 110392544 A		Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-6	EP	European Patent Convention		18713582.7	16-Mar-2018	3596124		Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-6	HK	Hong Kong		62020004401.9	18-Mar-2020	40015034A		Published	ANTIBODIES THAT INHIBIT SOLUBLE CD39
CD39-6	IL	Israel		269150	16-Mar-2018			Pending	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-6	IN	India		201917030892	16-Mar-2018			Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-6	JP	Japan		2019-55075.9	16-Mar-2018	2020-513809		Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-6	KR	Korea, Republic of		10-2019-7026886	16-Mar-2018	10-2019-0129866		Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-6	MX	Mexico		MX/a/2019/010848	16-Mar-2018	MX/a/2019/010848		Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-6	RU	Russian Federation		2019124687	16-Mar-2018			Pending	COMPOSITIONS AND METHODS FOR TREATING CANCER

CD39-6	US	United States of America	US 16,477,506	11-Jul-2019	20190369561	Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-6	US	United States of America	62/471,994	16-Mar-2017		Abandoned	ANTIBODIES THAT INHIBIT SOLUBLE CD39
CD39-6	US	United States of America	62/586,220	15-Nov-2017		Abandoned	ANTIBODIES THAT INHIBIT SOLUBLE CD39
CD39-6	WO	Patent Cooperation Treaty	PCT/EP2018/056663	16-Mar-2018	WO2018/167267	Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-8	AU	Australia	2018368541	15-Nov-2018		Pending	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	BR	Brazil	BR112020009655-5	15-Nov-2018		Pending	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	CA	Canada	3,075,371	15-Nov-2018	3075371	Published	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	CN	China (People's Republic)	2018960768596	15-Nov-2018	CN 11372606 A	Published	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	EA	Eurasian Patent Organization	202090551	15-Nov-2018	202090551	Published	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	EP	European Patent Convention	180039673	15-Nov-2018	3710052	Published	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	IL	Israel	273440	15-Nov-2018		Pending	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	JP	Japan	2020-526482	15-Nov-2018	2021-502380	Published	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	KR	Korea, Republic of	10-2020-7013452	15-Nov-2018	10-2020-0088811	Published	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	SG	Singapore	11202002195Y	15-Nov-2018		Pending	POTENTIATING THE EFFECT OF ATP RELEASE

23



CD39-8	US	United States of America	16/370789	29-Mar-2019	US 2019/0218304	Published	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	US	United States of America	52/586224	15-Nov-2017		Abandoned	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	US	United States of America	52/686349	18-Jun-2018		Abandoned	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	US	United States of America	52/733375	19-Sep-2018		Abandoned	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-8	WO	Patent Cooperation Treaty	PCT/EP2018/081364	15-Nov-2018	WO 2019/096900	Published	POTENTIATING THE EFFECT OF ATP RELEASE
CD39-9	AR	Argentina	20190101674	16-Jun-2019	AR15566A1	Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	AU	Australia	2019289646	17-Jun-2019		Pending	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	BR	Brazil	BR112020024412-0	17-Jun-2019		Pending	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	CA	Canada	3,099,893	17-Jun-2019	3099893	Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	CN	China (People's Republic)	2019800384483	17-Jun-2019	CN112334486A	Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	EA	Eurasian Patent Organization	202002518	17-Jun-2019	202092518	Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	EP	European Patent	197347115	17-Jun-2019	3807316	Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	GC	Gulf Cooperation Council	GC 2019 - 37764	18-Jun-2019		Abandoned	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	HK	Hong Kong	6202/030900.6	11-May-2021	40040395A	Published	COMPOSITIONS AND METHODS FOR TREATING CANCER

CD39-9	IL	Israel	278636	17-Jun-2019			Pending	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	IN	India	202017030930	17-Jun-2019			Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	JP	Japan	2020-570094	17-Jun-2019	2021-528063		Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	KR	Korea, Republic of	10-2021-7000691	17-Jun-2019	10-2021-6023983		Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	MX	Mexico	MX/a/2020/012107	17-Jun-2019			Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	SG	Singapore	1202012435U	17-Jun-2019			Pending	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	TW	Taiwan	108120819	17-Jun-2019	202016142		Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	US	United States of America	15/443744	17-Jun-2019	2020024357		Published	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	US	United States of America	62/666,165	18-Jun-2019			Abandoned	COMPOSITIONS AND METHODS FOR TREATING CANCER
CD39-9	WO	Patent Cooperation Treaty	PCT/EP2019/065877	17-Jun-2019	WO 2019/243252		Published	COMPOSITIONS AND METHODS FOR TREATING CANCER

*JS*  
PATENT